Hybridon and Aegera collaborate to develop antisense drug.
D017209:Apoptosis / Q000235:genetics; D002170:Canada; D003299:Cooperative Behavior; D004345:Drug Industry / Q000191:economics* / Q000458:organization & administration*; D006801:Humans; D008004:Licensure; D008404:Massachusetts; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D016376:Oligonucleotides, Antisense / Q000235:genetics* / Q000627:therapeutic use*; D011506:Proteins / Q000235:genetics*; D051636:X-Linked Inhibitor of Apoptosis Protein
D016376:Oligonucleotides, Antisense; D011506:Proteins; D051636:X-Linked Inhibitor of Apoptosis Protein; C496866:XIAP protein, human